MedTrace Logo

Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema

NCT01702441 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-03-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and pilot efficacy of multiple ascending dose levels of AKB-9778 given as subcutaneous injections daily for 28 days in patients with diabetic macular edema (DME).

Conditions

  • Diabetic Macular Edema (DME)

Interventions

DRUG

Subcutaneous AKB-9778

Sponsors & Collaborators

  • Aerpio Therapeutics

    lead INDUSTRY

Principal Investigators

  • Kevin Peters, MD · Aerpio Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-09-30
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01702441 on ClinicalTrials.gov